Big player grossly undervalued Here you can watch Dr. McIntyre who is a Prof in Psychiatry and Pharmacology describe why they are a big player in the market. (2 weeks ago)
https://youtu.be/wmE1GkqAwvQ
They have 4 clinics 2 NCE´s (New Chemical Entity) which focus on delivery systems of existing drugs and two Phase III clinical trial sponsored by 3rd parties (Canadian government). And they will expand into the US with up to 20 clinics.
No other psychedelic company was granted financial support by the government in this dimension.
Braxia gets direct billing (which is a milestone for all the psychedelic companies because it is the first of its kind reimbursement by health insurance of the break through therapies, wich are still off-label ant therefore not covered by Medical Insurance) , a Bipolar Study, and a Suicide Intervention Study
Field Trip has 8 clinics (US, Can, Europe) and ist around CA$ $7,4, but no ongoing trials above Phase I and only one NCE ( FT-104, is a synthetic psychedelic molecule for which anecdotal information indicates unique and useful pharmacological features**.** Field Trip anticipates initial Phase 1 clinical studies in 2021. A provisional patent relating to FT-104 composition)
https://www.meetfieldtrip.com/about/field-trip-discovery/default.aspx
Numinus has 2 clinics in Canada and ist at CA$ 0,97.
I can not see the future but it is highly unlikely that Braxia will not make it above these competitors in terms of stock price.
https://youtu.be/wmE1GkqAwvQ